| ID | 1212 |
| Name of the vaccine | Recombinant (dscCfaE) |
| Microbe | Bacteria |
| Disease name | E.coli Infections |
| Name of bacteria | Escherichia coli |
| Type of vaccine | Recombinant |
| Nucleic acid content | Circular duplex DNA |
| Age | 18 to 45 years |
| Description of the vaccine | Recombinant E. coli protein, dscCfaE with or without modified E. coli heat labile enterotoxin, LTR192G. |
| Name of the manufacturer | U.S. Army Medical Research and Development Command |
| Name of the manufacturing country | United States |
| Year of manufacture | 2013 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram-negative, rod-shaped bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Multiple combination of doses on study days 0, 21 and 42. |
| Mechanism of action | NA |
| Route of administration | Transcutaneous |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT01382095 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|